Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219407 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
A Phase 2 study of Epilepsy and Focal Epilepsy, sponsored by Rapport Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT07219407: Recruiting Phase 2 study of Epilepsy and Focal Epilepsy, sponsored by Rapport Therapeutics.
NCT07219407 is a Phase 2 study of Epilepsy and Focal Epilepsy that is actively recruiting participants, run by Rapport Therapeutics. The registered enrollment target is 30 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219407, a Phase 2 study of Epilepsy and Focal Epilepsy, is actively recruiting participants, sponsored by Rapport Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Conditions Studied
Interventions
- DRUG RAP-219
Study Locations (7)
Idaho
- Consultants in Epilepsy and Neurology, PLLC - Boise
Minnesota
- Mayo Clinic - Rochester
New York
- NYU Langone Comprehensive Epilepsy Center - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Pennsylvania
- University of Pennsylvania - Department of Neurology - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2028-02-03 |
| Phase | Phase 2 |
What NCT07219407 shows while recruiting
NCT07219407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which RAP-219 is the first listed.
NCT07219407 lists 7 locations in 7 states (Idaho, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT07219407 about?
NCT07219407 is a clinical study titled "A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures". This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
What is the current status of trial NCT07219407?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-12-15. Estimated completion is 2028-02-03.
What conditions does trial NCT07219407 study?
This clinical trial studies the following conditions: Epilepsy, Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure.
What interventions are being tested in trial NCT07219407?
The interventions under investigation include: RAP-219 (DRUG).
Who is sponsoring clinical trial NCT07219407?
This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219407 being conducted?
This trial has 7 study locations across Idaho, Minnesota, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219407's enrollment target sits among peer trials
30 109th of 160 higher than 41 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Pediatric Epilepsy Study in Subjects 1-24 Months
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI